NEUROCRINE BIOSCIENCES INC Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
NEUROCRINE BIOSCIENCES INC (NBIX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount of $8.30 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther · last filed 2026-02-11
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2025 was $8.30M.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2021 was $200.00K, a 66.67% decline from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2020 was $600.00K, a 25.00% decline from fiscal 2019.
- NEUROCRINE BIOSCIENCES INC effective income tax rate reconciliation, nondeductible expense, other, amount for fiscal 2019 was $800.00K, a 100.00% increase from fiscal 2018.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | $8.30M 10-K · filed 2026-02-11 | |
| 2021-12-31 | $200.00K 10-K · filed 2022-02-11 | |
| 2020-12-31 | $600.00K 10-K · filed 2022-02-11 | |
| 2019-12-31 | $800.00K 10-K · filed 2022-02-11 | $855.00K 10-K · filed 2020-02-07 |
| 2018-12-31 | $400.00K 10-K · filed 2021-02-05 | $446.00K 10-K · filed 2019-02-08 |
| 2017-12-31 | $433.00K 10-K · filed 2020-02-07 | |
| 2016-12-31 | -$321.00K 10-K · filed 2019-02-08 | |
| 2015-12-31 | $172.00K 10-K · filed 2018-02-13 | |
| 2014-12-31 | $10.00K 10-K · filed 2017-02-14 | |
| 2013-12-31 | $7.00K 10-K · filed 2016-02-11 | |
| 2012-12-31 | $9.00K 10-K · filed 2015-02-09 | |
| 2011-12-31 | $43.00K 10-K · filed 2014-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |